In the ever-evolving landscape of healthcare, groundbreaking innovations are not merely celebrated for their scientific ...

Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...

After years of weight loss drug shortages, the FDA is saying there's now an adequate supply for most medications and they ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

The exact price depends on dosage, pharmacy, location, insurance coverage, and available savings programs. Fully ...

Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...